The US Food and Drug Administration (FDA) has granted approval for Medtronic’s OmniaSecure defibrillation lead intended for ...

Omniasecure, which was authorized for placement in the heart’s right ventricle, is the world’s smallest defibrillation lead, ...

Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle ...

In order to remove obstacles preventing immediate defibrillation, the medical community and the media worked together to highlight the importance of public access defibrillation. Under increasing ...

A system hybridizing cardiac contractility modulation and implantable cardioverter defibrillation successfully converted ...

Medtronic (MDT) received U.S. Food and Drug Administration approval for the OmniaSecure defibrillation lead for placement within the right ...

Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for ...

As a provider of highly specialized OEM modules and a recognized expert in defibrillation and vital sign monitoring, ...

Kestra Medical Technologies today announced the presentation of new real-world data for its Assure wearable cardioverter ...

These observations have repositioned the ICD as primarily an ATP device with defibrillation backup only as needed. Tachycardias that require reentry to persist, are susceptible to termination with ...

(RTTNews) - Medtronic plc (MDT) said that it received U.S. Food and Drug Administration approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead ...

Medtronic said its OmniaSecure device can be used to treat potentially life-threatening conditions including ventricular tachyarrhythmias, a heart rhythm disorder where the heart's lower chambers beat ...